Novel antibiotic
Gepoditacin is a novel antibiotic currently in development. AB Direct is investigating treatment options for bacterial diseases caused by Neisseria gonorrhoeae and Escherichia coli. The aim is to demonstrate sufficient distribution of the active ingredient in tonsil and prostate tissue.
Together with research teams in France, the MedUni Vienna team led by Markus Zeitlinger is working on PBPK, PopPK and PK/PD models to gain a better understanding of the mechanism of action of gepoditacin and its distribution in tissue, and subsequently to evaluate various administration regimens.
The IMI project is receiving EU funding as the resistance of existing antibiotics is becoming a global problem and the WHO is prioritising the development of new treatment options. The successful implementation of the project will have a significant impact for the research community as well as for patients in the EU and worldwide.
‘Antibiotic resistance limits our ability to treat certain diseases. The search for alternatives is currently particularly important. With our microdialysis process, we can analyse the exact distribution of the novel active ingredient in the target tissue and predict its effectiveness very well.’